Expanding the role of coagulation in arterial thrombosis: Evidence from animal models using a new factor Xa inhibitor

• References

• 1 Eikelboom JW, Anand SS, Malmberg K. et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355: 1936-1942.
• 2 Eikelboom JW, Quinlan DJ, Mehta SR. et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a metaanalysis of the randomized trials. Circulation 2005; 112: 3855-3867.
• 3 Andreotti F, Testa L, Biondi-Zoccai G. et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27: 519-526.
• 4 Andreotti F, Becker RC. Atherothrombotic disorders. New insights from hematology. Circulation 2005; 111: 1855-1863.
• 5 ACTIVE Writing Group of the ACTIVE Investigators. Connolly S, Pogue J, Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
• 6 Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998; 351: 233-241.
• 7 Testa L, Zoccai GB, Porto I. et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol 2007; 99: 1637-1642.
• 8 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-360.
• 9 Ye Z, Liu EH, Higgins JP. et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658.
• 10 Hirsh J, O’Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin. Current and future advances. Circulation 2007; 116: 552-560.
• 11 Ansell J, Hirsh J, Poller L. et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204-233.
• 12 Kohrt JT, Bigge CF, Bryant JW. et al. The discovery of (2R,4R)-N-(4-chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor. Chem Biol Drug Des 2007; 70: 100-112.
• 13 Karnicki K, Leadley RJ, Baxi S. et al. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis. Thromb Haemost 2008; 99: 759-766.
• 14 Eisenberg PR. Novel antithrombotic strategies for the treatment of coronary artery thrombosis: A critical appraisal. J Thromb Thrombolysis 1995; 1: 237-249.